Publication: Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
Loading...
Open/View Files
Date
2018
Authors
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Pinter, Matthias, and Rakesh K. Jain. 2018. “Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.” Science translational medicine 9 (410): eaan5616. doi:10.1126/scitranslmed.aan5616. http://dx.doi.org/10.1126/scitranslmed.aan5616.
Abstract
Renin-angiotensin system (RAS) inhibitors (RASi)—widely prescribed for the treatment of cardiovascular diseases— have considerable potential in oncology. The RAS plays a crucial role in cancer biology and affects tumor growth and dissemination directly and indirectly by remodeling the tumor microenvironment. We review clinical data on the benefit of RASi in primary and metastatic tumors and propose that, by activating immunostimulatory pathways, these inhibitors can enhance immunotherapy of cancer.
Description
Other Available Sources
Research Data
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service